NO RADIOGRAPHIC SACROILIITIS PROGRESSION OVER 6 YEARS IN PATIENTS WITH EARLY Spondyloarthritis FROM THE ESPERANZA COHORT

C. Tornero1, M. D. C. Castro Villegas2, X. Juanola-Roura3, M. L. García-Vivar4, C. Fernández-Carballoido5, J. F. García Lorente6, B. Joven-IBañez7, E. Galíndez8,9, C. Urengo-Laurin10, E. De Miguel11 on behalf of Esperanza Working Group; 1Hospital Universitario La Paz, Rheumatology, Madrid, Spain; 2Hospital Reina Sofia, Rheumatology, Córdoba, Spain; 3Hospital Universitario de Bellvitge, Rheumatology, Barcelona, Spain; 4Hospital Universitat Basurto, Rheumatology, Bilbao, Spain; 5Hospital Universitario San Juan, Rheumatology, Alicante, Spain; 6Hospital de Galdakao, Rheumatology, Bilbao, Spain; 7Hospital 12 de Octubre, Rheumatology, Madrid, Spain; 8Hospital Universitario de Basurto, Bilbao, Spain; 9Hospital Universitario Moncloa, Rheumatology, Madrid, Spain

Background: Longitudinal studies about the change from non-radiographic axial Spondyloarthritis (nr-axSpA) to r-axSpA (radiographic axial Spondyloarthritis) are scarce but show a 9-10% progression rate over 2 years (1-2) and a 24% progression rate over 10 years in another study (3). However, in early cohorts such as DESIR, this only represents a 5% over 5 years (4).

Objectives: The aim of this study was to know the rate of progression from nr-axSpA to r-axSpA over 6 years.

Methods: This study included 94 patients of the Spanish early spondyloarthritids (SpA) Esperanza cohort, 60 fulfilled the ASAS classification criteria for SpA. Every patient had a baseline and a six-year sacroiliac X-ray. Nine readers, blinded for the diagnosis, participated in the reliability exercise, all of them experienced rheumatologists and members of the Spanish spondyloarthritis working group (GRESSER). Patients with SpA were classified as having r-axSpA at baseline or after 6 years of follow-up, if they fulfilled the radiographic item of the modified New York criteria (mNY) (presence of radiographic changes in the sacroiliac joints -SJu- of at least grade II bilaterally or grade III or IV unilaterally). The gold standard of SJu X-Ray was the categorical opinion of at least five of sacroiliac joints -SJu- of at least grade II bilaterally or grade III or IV unilaterally).

Results: Demographic data of the SpA patients were: mean age 33.4±7.5 years; 37 (61.7%) male; mean CRP 6.4±6.5 mg/dl and ESR 10.3±10.6. Present smokers 30.6%; and past smokers 16.3%. HLA-B27 (+) 56.7%. Regarding the presence of X-Ray sacroiliitis: 20 patients had baseline sacroiliitis and 18 at the final visit; 11 had sacroiliitis at both baseline and final visits; 9 patients changed from baseline sacroiliitis to no-sacroiliitis and 7 changed from baseline no-sacroiliitis to sacroiliitis at the 6 year visit. The reliability of the readers was fair with a mean inter-reader kappa test of 0.375 (range 0.146 - 0.652) and a mean agreement of 73.3% (range 58.7% - 90%).

Conclusion: In this group of patients with early SpA no progression from nr-axSpA to r-axSpA over 6 years was observed. It appears that early diagnosis and standard treatment seem to reduce SJu radiographic progression.

References:

Disclosure of Interests: Carolina Tornero: None declared, María del Carmen Castro Villegas: None declared, Xavier Juanola-Roura: None declared, María Luz García-Vivar: None declared, Cristina Fernández-Carballoido: Consultant of: Yes, I have received fees for scientific advice (Abbvie, Celgene, Janssen, Lilly, Novartis, Pfizer, Roche), Speakers bureau: Yes, I have received fees as a speaker (Abbvie, Celgene, Janssen, Lilly, Novartis, Pfizer, Roche), Takeda, Speakers bureau: Abbvie, CED Service GmbH, Falk, Ferring, Janssen, Novartis, Takeda (BS served as representative of the Charité), Denis Podubnyj Grant/research support from: Abbvie, MSD, Novartis, Pfizer, Consultant of: Abbvie, Bristol-Myers Squibb, Eli Lilly, MSD, Novartis, Pfizer, Roche, UCB, Speakers bureau: Abbvie, Bristol-Myers Squibb, Eli Lilly, MSD, Novartis, Pfizer, Roche, UCB, Speakers bureau: Abbvie, Bristol-Myers Squibb, Eli Lilly, MSD, Novartis, Pfizer, Roche, UCB.

DOI: 10.1136/annrheumdis-2020-eular.4718
associated in multivariate analysis with the following baseline factors: diagnosis of SpA (OR 9.65 [3.21 – 28.96]; p=0.039*), total sacro iliac MRI inflammatory SPARRC score (central reading) over median (OR 3.98 [2.26 – 7]; p=0.015*), dactylitis (OR 4.7 [2.65 – 8.36]; p=0.007**), syndesmophyte score over median (central reading) (OR 0.22 [0.1 – 0.45]; p=0.039*).

No significant association was found with HLA-B27, cs or b DMARDs, BSAID, ASASD, BASFI.

Conclusion: Five-years data of the DESIR cohort allowed an estimation rate of uveitis of 1.3/100p-y; over five years, uveitis was associated with dactylitis, biologic and sacro iliac MRI inflammation.

References:

Disclosure of Interests: Daniel Wendling: None declared, Clément Prat: None declared, Thierry Lequerre: None declared, Corinne Miceli Richard: None declared, Maxime Dugados Grant/research support from: AbbVie, Eli Lilly, Merck, Novartis, Pfizer and UCB Pharma, Consultant of: AbbVie, Eli Lilly, Merck, Novartis, Pfizer and UCB Pharma, Speakers bureau: AbbVie, Eli Lilly, Merck, Novartis, Pfizer and UCB Pharma, Anna Moltò Grant/research support from: Pfizer, UCB, Consultant of: Abbvie, BMS, MSD, Novartis, Pfizer, UCB, xavier guilhot: None declared

DOI: 10.1136/annrheumdis-2020-eular.1554

FR10326
PREVALENCE AND IMPACT OF COMORBIDITIES IN AXIAL SPONDYLOARTHRITIS: SYSTEMATIC REVIEW AND META-ANALYSIS
S. S. Zhao1,2, S. Robertson1, T. Reich1, N. L. Harrison3, R. J. Moots1,2, N. Goodson1,2, 1University of Liverpool, Liverpool, United Kingdom; 2Aintree University Hospital, Liverpool, United Kingdom

Background: Comorbidities are common among patients with axial spondyloarthritis (axSpA). The majority of axSpA patients have at least one comorbid medical condition in addition to any extra-articular manifestations [1]. Comorbidity ‘burden’ is associate with poorer function, quality of life and work-related outcomes [2]. They also influence treatment decisions and are key drivers of mortality.

Objectives: We performed a systematic review and meta-analysis to 1) describe the prevalence of commonly reported comorbidities, 2) compare the prevalence of comorbidities between axSpA and control populations.

Methods: A systematic review was performed in September 2019 using Medline, PubMed, Scopus and Web of Science, in accordance with PRISMA guidelines. Studies were included if they reported the prevalence of comorbidities on disease outcomes, and excluded if they focused on a single comorbidity or closely related diseases in one system. Two independent reviewers screened titles and abstracts, assessed full-texts for eligibility and extracted data from qualifying studies. Where possible, we performed meta-analyses for comorbidities reported by at least 3 studies using random-effects models. Pooled prevalence estimates were reported as percentages (95% confidence interval, I2 statistic for heterogeneity).

Results: 36 studies reported prevalence of 18 individual comorbidities, amounting to a combined sample size of 119,427 patients. The most prevalent individual comorbidities were hypertension (pooled prevalence 22%), hyperlipidaemia (17%) and obesity (14%) (Figure 1). Eleven studies consistently showed higher prevalence of comorbidities in axSpA than controls (Table 1); odds ratios (OR) were particularly large for depression (pooled OR 1.80) and congestive cardiac failure (OR 1.84). There was significant heterogeneity for the majority of meta-analysis estimates.

Table 1. Meta-analysis estimates for odds ratios (OR) of comorbidities compared between axSpA and control groups.

<table>
<thead>
<tr>
<th>Comorbidity</th>
<th>Number of studies</th>
<th>Pooled OR</th>
<th>95% confidence interval</th>
<th>I2 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypertension</td>
<td>9</td>
<td>1.58</td>
<td>1.29 to 1.92</td>
<td>98</td>
</tr>
<tr>
<td>Any cardiovascular disease</td>
<td>3</td>
<td>1.42</td>
<td>0.999 to 2.03</td>
<td>99</td>
</tr>
<tr>
<td>Any ischaemic heart disease</td>
<td>7</td>
<td>1.51</td>
<td>1.21 to 1.87</td>
<td>87</td>
</tr>
<tr>
<td>Congestive cardiac failure</td>
<td>4</td>
<td>1.84</td>
<td>1.55 to 2.23</td>
<td>89</td>
</tr>
<tr>
<td>Stroke</td>
<td>6</td>
<td>1.30</td>
<td>1.04 to 1.62</td>
<td>81</td>
</tr>
<tr>
<td>Peripheral vascular disease</td>
<td>5</td>
<td>1.47</td>
<td>1.10 to 1.96</td>
<td>83</td>
</tr>
<tr>
<td>Diabetes</td>
<td>8</td>
<td>1.14</td>
<td>1.00 to 1.30</td>
<td>83</td>
</tr>
<tr>
<td>Hyperlipidaemia</td>
<td>5</td>
<td>1.18</td>
<td>1.01 to 1.39</td>
<td>94</td>
</tr>
<tr>
<td>Cancer</td>
<td>5</td>
<td>1.22</td>
<td>1.01 to 1.47</td>
<td>93</td>
</tr>
<tr>
<td>Depression</td>
<td>4</td>
<td>1.80</td>
<td>1.45 to 2.23</td>
<td>92</td>
</tr>
</tbody>
</table>

Conclusion: Comorbidities are common in axSpA. Almost all comorbidities examined were more prevalent in axSpA patients than age and sex matched controls, with ≥80% higher odds for congestive cardiac failure and depression. Systematic and repeated assessments should therefore be integrated into routine clinical practice to ensure holistic patient-centred management. Additional studies are needed to validate comorbidities indices for axSpA research.

References:


Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.1252

FR10327
QUALITY OF LIFE, QUALITY OF SLEEP AND PRESENCE OF RESTLESS LEG SYNDROME IN ANKYLOSING SPONDYLITIS
S. Zontul1, A. K. Cengiz2, Z. Altay3. 1Ministry of Health Batman District Hospital, Rheumatology, Batman, Turkey; 219 Mayis University Faculty of Medicine, Physical Medicine and Rehabilitation-Rheumatology, Samsun, Turkey; 3Inonu University Faculty of Medicine, Physical Medicine and Rehabilitation, Malatya, Turkey

Background: For chronic diseases like ankylosing spondylitis (AS), improving patients quality of life (QOL) is one of the main aims of the therapy. Sleep quality is an important determinant of QOL. Restless leg syndrome (RLS) is a frequent disorder that disturbs patients QOL.

Objectives: The aim of this study is to evaluate the sleep quality of patients with AS and to determine the possible reasons of sleep disorder like pain, disease activity, functional status, depression, anxiety, presence of RLS and their impact on patients QOL.

Methods: One hundred twenty two patients with ankylosing spondylitis were enrolled in the study. Quality of life was evaluated by using short form-36 (SF-36). Beck depression and Beck anxiety indices were used to evaluate the mood of the patients. Sleep quality was determined with Pittsburgh Sleep Quality Index. International Restless Leg Study Group (IRLSSG) criteria was used to determine the co-existing restless leg syndrome. Demographic data including age, sex, height, weight, marital status, educational status, disease duration and medical treatments were noted. BASDAI (Bath ankylosing spondylitis disease activity index),BASMI (Bath ankylosing spondylitis metrology index) and BASFI (Bath ankylosing spondylitis functional index) are determined and perceived pain level was evaluated by visual analog scale for pain (VASpain) for all patients.

Results: According to Pittsburgh Sleep Quality Index 48 patients (39.3%) had bad sleep quality. When patients with bad sleep quality were compared with the patients with good sleep quality according to SF-36, BASDAI, BASMI,BASFI, VAS pain, Beck depression and Beck anxiety indices worse scores were obtained in patients with bad sleep quality. The difference between two groups were statistically significant for almost all of the listed parameters (Table 1). Restless leg syndrome (RLS) was determined in 36.06% (44/122) of AS patients. RLS was more common in patients with bad sleep quality but the difference did not reach statistical significance.

Figure 1. Pooled prevalence of individual comorbidities.